Medical Device Developments的动态

Efficient, accurate and reliable diagnosis of breast cancer is more crucial than ever for improving patient outcomes.? As treatments become increasingly targeted and personalized, diagnostics play a pivotal role in guiding therapy decisions. MammaTyper? is an innovative diagnostic tool that empowers clinicians to customize treatments effectively, leading to better outcomes. Its affordability and accessibility make it an invaluable asset for hospitals striving to deliver top-notch care. We've been sharing insights through our new film series on the role of MammaTyper? in breast cancer diagnosis and treatment. Now you can watch these discussions in full. In this film we explore the forefront of breast cancer care, featuring leading experts including Prof. Daniele Generali, Dr. Dana Cohen, Professor John Bartlett, and Dr. Dario de Biase.? We want MammaTyper? to shape better outcomes for all patients with breast cancer. #BreastCancer #MammaTyper #PersonalizedMedicine #HealthcareInnovation

Honoring Breast Cancer Awareness Month This October, Viscadia recognizes Breast Cancer Awareness Month and reaffirms our commitment to supporting innovation in Breast Cancer treatment. Raising awareness and supporting patients, researchers, and healthcare professionals is key in the fight against this disease. In line with our mission, we invite you to revisit one of our archived webinars?hosted by Satish Kauta, Shruti Gupta and Anindya Roy, where our specialists cover critical topics in forecasting for Breast Cancer treatment. Key areas include: ? Market dynamics for emerging Breast Cancer therapies ? Advanced forecasting models to support decision-making in treatment development ? Insights into evolving treatment pathways and patient care Take this opportunity to explore how forecasting can contribute to better healthcare outcomes for Breast Cancer patients. https://lnkd.in/ekpkQzAg #BreastCancerAwareness #HealthcareInnovation #ForecastingSolutions #BreastCancerResearch #LifeSciences #Viscadia

Breast cancer is the second most common cancer worldwide and the number one cancer in women. In 2022 alone, there were over 2.2 million new breast cancer cases worldwide! To commemorate Breast Cancer Awareness Month this October, we are proud to showcase how Medix acts as a partner to breast cancer patients throughout their entire medical journey. From expert multidisciplinary medical advice to complete coordination of care, to ongoing guidance and support, Medix provides high quality services that deliver better medical outcomes.????? ? In 52% of breast cancer cases managed, Medix suggested a more optimal treatment plan. ? In 13% of cases managed, Medix helped prevent unnecessary major procedures or surgeries.? ? And in 7% of cases managed, Medix reversed or provided a more accurate diagnosis that significantly impacted outcomes. With Medix you are not alone, and no stone is left unturned. Learn more about Medix’ personal medical case management services here: https://lnkd.in/ePHuhmzG #BreastCancerAwarenessMonth #BreastCancer #CaseManagement #CareNavigation #MedicalJourney

Frontline treatment for HER2+ metastatic breast cancer has remained mostly unchanged for over a decade. Just to be revolutionized over one single year - First, the EMERALD trial at ASCO24, showing non-inferiority of an eribulin (vs taxane) backbone for HP. - Then, PATINA, stunning the SABCS24 auditorium with the longest PFS ever seen for this disease, through the addition of palbociclib. - And soon, DESTINY-Breast-09, with the highly anticipated substitution of first-line chemo with an ADC (T-DXd). This all means huge opportunities for patients, but also relevant challenges to make the most adequate therapeutic choice in a rapidly evolving landscape. In our latest JCO editorial, accompanying the brilliant EMERALD trial publication, Tess O'Meara, MD, MHS and I review these evolutions in the treatment of HER2+ breast cancer, suggesting a framework to select the most appropriate first-line treatment. Read it here: https://lnkd.in/g7hqc2ih

According to the WHO, #lungcancer remains the leading cause of cancer deaths worldwide. We are seeing early detection change this narrative. This Lung Cancer Awareness Month, Johnson & Johnson Interventional Oncology is at the forefront of innovation, developing innovative diagnostic tools. These advancements enable physicians to identify solutions to treat lung cancer with greater precision. Take Deborah Borst, for instance. Diagnosed with lung cancer while being treated for a kidney stone, early detection allowed her to receive personalized care and become cancer-free in six months. Stories like Deborah’s are what we strive for at #JNJ. By leveraging our expertise and commitment to patient safety across Innovative Medicine and MedTech, we aim to transform the patient treatment journey, providing effective cancer treatment while minimizing potential risks and recovery time. Read more about Deborah’s journey here: https://lnkd.in/epYR9pMa #MyCompany #LungCancerAwarenessMonth #InFrontofCancer

Anthracyclines like doxorubicin (often called the 'red devil' for its distinct red color and severe side effects) are used in 40-50% of breast cancer regimens for a 5-10% survival boost. However, they carry significant cardiotoxicity risks, primarily manifesting as heart failure, with up to 9% of patients affected and a 26% risk at cumulative doses of 550 mg/m2. Check out our one-pager below for more information! Download PDF here: https://lnkd.in/epr9EQvU ??? October is Breast Cancer Awareness Month ??? In recognition of this, we will be releasing daily one-pagers this week, featuring educational literature on breast cancer. We aim to provide healthcare professionals with valuable, evidence-based insights to support awareness and action. #breastcancerawareness #evidencebased #stayinformedwithInpharmD

Mammograms are the best screening tests for breast cancer currently available. However, some people may hesitate to take one due to certain misconceptions. See if you can answer if this is a #MythorFact. ----------------------------------------------------------------------------------- If you answered myth, then you are correct. Regular mammograms can find signs of breast cancer years before physical symptoms can be felt, such as unusual lumps, swelling and other breast abnormalities. However, some cases of early-stage breast cancer may not show signs or symptoms, which is why early screening is important. Is it time for your mammogram? Talk to our navigator today! Visit here to sign up: https://lnkd.in/eegvxsAp #StrongerTogetherForYou #PBHNProud #MondayMyth #Mammogram

11 compelling reasons to get screened during Breast Cancer Awareness Month: 1. Screening increases chances of detecting breast cancer at an early stage. 2. Early detection improves treatment options and survival rates. 3. Screening helps identify cancer before symptoms appear. 4. Regular screening reduces risk of advanced cancer. 5. Early detection provides more treatment choices. 6. Screening helps identify cancer type and stage. 7. Screening contributes to higher survival rates. 8. Screening provides reassurance and reduces anxiety. 9. Knowing your Breast Health status helps you take control. 10. Screening educates you about breast health and the Knowledge helps you make informed decisions. 11. Screening promotes breast cancer awareness and Educate yourself and others about breast health. Get your FREE Breast screening in one of our locations this month! Tell, Tag and Repost #knowyourbreasthealthstatus

??? October is Breast Cancer Awareness Month! This month is dedicated to raising awareness, supporting research and ensuring that every patient receives timely care. We proudly recognize the tireless efforts of organizations like the Quebec Breast Cancer Foundation and the Canadian Cancer Society, who work not only during October but throughout the year to drive progress in research, education and support for those affected by breast cancer. ?? As we reflect on the progress made in cancer care, it’s clear that technology plays a vital role in bridging geographical barriers, enhancing patient engagement, and improving health outcomes. Together, let's explore how innovations in digital health can enhance breast cancer care, ensuring timely diagnoses, personalized treatments and better overall support for patients throughout their journey. To learn how we can support your healthcare initiatives and improve breast cancer care:??? https://lnkd.in/d6CYpU8E #breastcancerawareness #pinkoctober #digitalhealth?#innovation #oncology

Recognizing the Importance of Early Detection: With one in eight women expected to develop breast cancer during their lifetime, per the CDC, early detection is the key to saving lives. When discovered early, and in the localized stage, the 5-year relative survival rate for breast cancer is 99%, per the American Cancer Society. The most important screening test for breast cancer is a mammogram, an X-ray of the breast that can detect breast cancer up to two years before the tumor can be felt by you or your doctor. “Patients should start anywhere between the ages of 40 and 50 and then get mammograms on an annual basis,” advises Dr. Audrey Gonzalez, MD, a family medicine physician with STHS Clinics. To schedule a mammogram, call #STHS Pre-Registration at (956) 388-2190. For more information on mammograms, check out our latest South Texas Health Minute on ValleyCentral.com. bit.ly/3VwvKzH